Univ.-Klinik für Radiodiagnostik, Division für Molekulare und Gender-Bildgebung, Medizinische Universität Wien, Währinger Gürtel 18-20, A-1090, Wien, Österreich.
In recent years magnetic resonance imaging (MRI) has been increasingly established in the diagnosis of prostate cancer in addition to transrectal ultrasonography (TRUS). The use of T2-weighted imaging allows an exact delineation of the zonal anatomy of the prostate and its surrounding structures. Other MR imaging tools, such as dynamic contrast-enhanced T1-weighted imaging or diffusion-weighted imaging allow an inference of the biochemical characteristics (multiparametric MRI). Prostate cancer, which could only be diagnosed using MR imaging or lesions suspected as being prostate cancer, which are localized in the anterior aspect of the prostate and were missed with repetitive TRUS biopsy, need to undergo MR guided biopsy. Recent studies have shown a good correlation between MR imaging and histopathology of specimens collected by MR-guided biopsy. Improved lesion targeting is therefore possible with MR-guided biopsy. So far data suggest that MR-guided biopsy of the prostate is a promising alternative diagnostic tool to TRUS-guided biopsy.
Article in German.
Written by:
Schernthaner M, Helbich TH, Fueger BJ, Margreiter M, Memarsadeghi M, Stiglbauer A, Linhart HG, Doan A, Pinker K, Brader P. Are you the author?
Reference: Radiologe. 2011 Oct 21. Epub ahead of print.
doi: 10.1007/s00117-011-2180-4
PubMed Abstract
PMID: 22012569
UroToday.com Prostate Cancer Section
